trimethobenzamide-hydrochloride and Apomorphine Interactions

Interactions between trimethobenzamide-hydrochloride(trimethobenzamide) and Apomorphine (apomorphine)

trimethobenzamide and apomorphine (Moderate Drug-Drug)

MONITOR: Central nervous system effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients. Both trimethobenzamide and apomorphine have sedative properties. Patients may suddenly fall asleep during activities of daily living while on apomorphine therapy. In clinical trials (n=522), trimethobenzamide was used for up to 33 months for the prevention and treatment of apomorphine-induced nausea and vomiting and appeared to be tolerated well. The manufacturer recommends starting trimethobenzamide (300 mg orally three times a day) before the first dose of apomorphine is given.

MANAGEMENT: Monitoring for potentially excessive or prolonged CNS depression is recommended. Patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them. If patients experience increased episodes of falling asleep during normal daily activities, they should avoid driving and other potentially hazardous activities until they have contacted their physician.